2d agoSEC 8-KNEUTRAL 50General
Disc Medicine, Inc. (IRON) files 8-K
Filed: 2026-09-10 AccNo: 0001193125-26-387351 Size: 206 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Archived explainer. For the current picture see today's IRON page.
Why Is DISC MEDICINE INC (IRON) Stock Down Today?
By the Top Tier Newswire AI Desk · September 11, 2026 at 1:17 PM ET · reviewed against 5 wire stories
DISC MEDICINE INC (IRON) is down -5.11% in the latest session. Our newswire has captured 5 stories on IRON across 3 sources in the last 36 hours, with AI sentiment reading mixed (avg 57/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Why IRON stock is down today
Disc Medicine Inc (IRON) fell 5.11% to $70.36 in afternoon trading on Wednesday. The decline came amid a flurry of analyst activity and a recent SEC filing that may have raised investor concerns. The stock opened at $74.00 but quickly reversed direction, hitting a session low of $70.14 before settling near the bottom of the range.
What Happened
Disc Medicine filed a Form 8-K with the SEC on September 10, disclosing information under Regulation FD and other events. The filing included financial statements and exhibits but did not provide specific details on the nature of the events. This regulatory activity coincided with multiple analyst reports reiterating or adjusting their ratings. H.C. Wainwright, Jefferies, and BMO all maintained or reaffirmed their positive outlooks based on ongoing trial data. However, the market reacted negatively, possibly due to the timing of the SEC filing or broader uncertainty.
Recent insider transactions also drew attention. Director Kevin Bitterman and COO Jonathan Yen-Wen Yu sold shares in late August and early September. The insider selling totaled $15.9 million in the last 90 days, with no buys reported. This activity may have contributed to a cautious tone among investors.
What The Data Shows
The stock opened sharply higher but reversed course, trading below the morning high. Volume was 0.1 million shares, or 0.3 times the 3-month average, indicating limited participation. The stock has traded in a wide range over the past 52 weeks, from $40.00 to $99.50, and is currently near the lower end. It has also printed 24 fresh 52-week lows on September 11, highlighting the bearish pressure.
Disc Medicine remains unprofitable with a trailing twelve-month EPS of -6.56 and a market cap of $2.9 billion. The stock has a beta of 2.05, making it more volatile than the broader market.
What To Watch
Investors should monitor the company’s next earnings report and any further developments from its RESTORE-PV trial. Analyst coverage and insider activity will also remain key indicators for the stock’s near-term direction.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
IRON by the numbers
Last: $70.36Session: -5.11%7 sessions: +2.47%Coverage: 5 stories / 3 sourcesAI sentiment: 57/100 (mixed)Mkt cap: $2.9B52w: $40.00 to $99.50
The headlines behind the move
3d agoInvesting.com Analyst RatingsBULLISH 56Analyst
H.C. Wainwright reiterates Disc Medicine stock rating on trial data
H.C. Wainwright reiterates Disc Medicine stock rating on trial data
3d agoInvesting.com Analyst RatingsBULLISH 56Analyst
Jefferies reiterates Disc Medicine stock rating on polycythemia data
Jefferies reiterates Disc Medicine stock rating on polycythemia data
3d agoInvesting.com Analyst RatingsBULLISH 61Analyst
Disc Medicine stock rating held at Outperform by BMO on trial data
Disc Medicine stock rating held at Outperform by BMO on trial data
3d agoGlobeNewswireBULLISH 63Product/PR
Disc Medicine Presents Initial Results from RESTORE-PV Phase 2 Trial in Patients with Polycythemia Vera (PV) at the 14th Society of Hematologic Oncology (SOHO) Annual Meeting
Initial results from RESTORE-PV show DISC-3405 increased hepcidin and lowered serum iron, translating to controlled hematocrit, reduced phlebotomy, and improved symptoms in PV...
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on IRON: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier IRON move explainers: 2026-09-11